WiCON | Pharma China (Web Edition)

The Market

Industry News

Regulatory News

General Health

	Revisiting the Basis of Your China Strategy in the Post-Covid New Normal
	Chief Editor James Shen offers his monthly review of the Chinese healthcare sector with this issue's emphasis on confronting the realities and challenges of Chinese marke... (7/1/2020)

Revisiting the Basis of Your China Strategy in the Post-Covid New Normal (7/1/2020)

Trends in U.S. Multinational Enterprise Activity in China, 2000-2017 (7/1/2020)

Ex-USPTO Head, Retired Judge Back China Pharma IP Reform (6/30/2020)

How Data Protection Matters for Pharma Cos in Mainland China? - Ensuring Compliance and Mitigating Risk (6/30/2020)

In Depth: Decoding China's First Civil Code (6/23/2020)

Dealing with the Chinese Economy after COVID-19 (6/3/2020)

Chinese Antitrust Authority Imposes Maximum Fine In Rare Abuse Of Collective Dominance Case (6/1/2020)

Despite Stormy Days Ahead, Pockets of Hope and Opportunity Remain (6/1/2020)

Challenges Posed to Chinese Biotechs in Post-Pandemic Era (5/28/2020)

Considerations on the Protection of Remdesivir under Trademark Law (5/26/2020)

COVID-19 Makes Digital Care the Norm in China (5/21/2020)

As China Stumbles, India Plans Big Exports Push in Bulk Drugs (5/20/2020)

Trump Is Investing Millions to Bring Drug Making Back to US From India and China (5/20/2020)

How the Coronavirus Is Helping to Fix China’s Broken Healthcare System (5/19/2020)

China's Role in The Global Biotechnology Sector and Implications for US Policy (5/14/2020)


	Recent Executive Moves (7/10/2020)
	State Council Issues Guidance Opinions o... (7/10/2020)
	CDE Launches Updated Drug Clinical Trial... (7/10/2020)
	CDE Launches Online Application Systems ... (7/10/2020)
	Merck's MilliporeSigma Opens its Largest... (7/9/2020)
	Evive Biotech Meets Endpoints in Global ... (7/9/2020)
	Asieris Received Chinese Approval to Sta... (7/9/2020)
	Chinese Alzheimer’s Drug Rebuked Again ... (7/9/2020)
	Roche Launches Collaborative Program in ... (7/9/2020)
	CDE Issues the Guidelines for Format/Sty... (7/9/2020)
	Clover Biopharma Receives $66M from CEPI... (7/9/2020) (free)
	NMPA Issues the Working Procedure for Pr... (7/8/2020)
	NMPA Issues Working Procedures for Drug ... (7/8/2020)
	NMPA Issues Working Procedures for Evalu... (7/8/2020)
	GSK Files New Drug Application for IL-5 ... (7/8/2020)

	Pfizer to Absorb Mylan, Creating Global Generic Powerhou...
	PhRMA Calls for Trade Deals That Force Countries to Pay ...
	IQVIA: Global Pharma to Grow Slower in the Next Five Yea...
	Pfizer and GSK Announce JV to Create a Global Consumer H...
	Top 25 Global Pharmaceutical Companies by Market Cap 201...

	EU Chamber of Commerce Publishes Its China Business Confidence ...
	PHIIC: Urban Chinese Hospital Drug Market Declined 25% in Q1
	SMEI Bluebook 2020: Chinese Retail Pharmacy Market (Offline and...
	SMEI Bluebook 2020: Urban and County Level Public Hospital Drug...
	NH Reports 5% Growth for 2019 OTC Gastrointestinal Market in Ch...

	Merck's MilliporeSigma Opens its Largest M Lab Collaboration...
	Roche Launches Collaborative Program in China for Digestive ...
	Clover Biopharma Receives $66M from CEPI for COVID-19 Vaccin...
	Turning Point and Zai Lab Announce Exclusive License Deal fo...
	SinoPharm Completes New Vaccine Plant in Wuhan, Doubling Cap...

	CDE Launches Updated Drug Clinical Trial Registration an...
	CDE Launches Online Application Systems for Breakthrough...
	CDE Issues the Guidelines for Format/Style and Collation...
	NMPA Issues the Working Procedure for Priority Review an...
	NMPA Issues Working Procedures for Drug Marketing Evalua...

	NPC Solicits Comments on 2nd Draft of the Chinese Patent Law...
	Punitive Damages in China's New Civil Code
	SAMR Issues Notice to Strengthen Anti-Unfair Competition Enf...
	Beijing Plans to Criminalize Criticisms of Traditional Chine...
	NPC to Prioritize Legislation on Public Health in 2020

	Fitch: No Near-Term Impact on Chinese API Makers as Phar...
	Indian Firms Challenged by API Price Hikes by Chinese Su...
	Snapshot of the Chinese API Sector
	India to Boost API Output as Alternative Source to China...
	India Lifts Export Restrictions on 24 APIs

	Evive Biotech Meets Endpoints in Global PIII Trial for N...
	Asieris Received Chinese Approval to Start a Global Phas...
	Chinese Alzheimer’s Drug Rebuked Again by Top Local Neu...
	GSK Files New Drug Application for IL-5 mAb Nucala (Mepo...
	Sinovac Begins Phase III Trial of Its Coronavirus Vaccin...

	State Council Issues Guidance Opinions on Advancing BMI ...
	Swiss Re: Chinese Online Health Insurance Market to Grow...
	Central Government Issues Notice on Urban and Rural Resi...
	NHSA Issues the Subgrouping Plan of BMI Diagnosis Relate...
	State Council Highlights Major Tasks in the Healthcare S...

	Recent Executive Moves
	Senior Chinese Pharma Official Investigated for Serious Le...
	Recent Executive Movements
	Recent Executive Movements
	Recent Executive Moves

	USTR Satisfied with China's Implementatin of Phase 1 US-...
	U.S.-China ESRC Hearing: China’s Evolving Healthcare Sy...
	AmCham Survey: Supply Chain Challenges for US Companies ...
	Upcoming Event: 2nd World Congress on Dermatology and Ae...
	Upcoming Event: XI International Exhibition of Equipment...

Pharma China is the most influential English media and source of business intelligence covering the Chinese pharmaceutical and biopharmaceutical sector...

WiCON has been helping international healthcare companies succeed in China and other Asian markets since 1991. We advise our clients on every stage of their China and Asian business. We worked with clients in many regions of the world...

WiCON Publishes the China Phar...

WiCON to Hold Pharma China Ann...

WiCON Publishes the China Phar...

WiCON Officially Publishes Chi...

Site map | Contact Us | Links